Skip to main content
SpringerLink
Log in

Crystal-Induced Arthritis

  • Reference work entry
  • First Online:
Geriatric Diseases

  • 1573 Accesses

Abstract

The incidence of gout seems to be rising in the elderly, both in men and women in countries where the life expectancy is lengthening and the frequency of overuse of diuretics. Gout predominantly affects the middle ages and elderly people and rarely occurs in young adult or children. CPPD crystal deposition disease is the second most common form of crystal-induced arthritis and is common in the elderly. The chapter discusses the pathogenesis of gout and clinical management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 379.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Eggebeen AT. Gout: an update. Am Fam Physician. 2007;76:801–8.

    PubMed  Google Scholar 

  2. De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F, Elderly-onset gout: a review. Rheumat Int. 2007;28:1–6.

    Article  Google Scholar 

  3. Fam AG. Gout in the elderly: Clinical presentation and treatment. Drugs Aging. 1998;13:229–243.

    Article  CAS  PubMed  Google Scholar 

  4. Staessen J. The determination and prognostic significance of serum uric acid in elderly patients of the European Working Party high blood pressure on the Elderly trial. Am J Med. 1999;90(3A):50S–54S.

    Google Scholar 

  5. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight changes, hypertension, diuretic use and risk of gout in men: the health professional follow-up study. Arch Intern Med. 2005;165:742–8.

    Article  PubMed  Google Scholar 

  6. Arromdee E, Michet CJ, Growson CS, Fallon S, Gabriel SE. Epidemiology of gout: Is the incidence rising? J Reumatol. 2002;29:2403–6.

    Google Scholar 

  7. Mikuls TR, Farrar JT, Bilker WNB, Fernsndes S, Schumacher HR Jr, Saag KG. Gout epidemiology: Results from the United Kingdom general practice research data base. 1990–1999. Ann Rheum Dis. 2005;64:267–272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Matsuo H, Ichida K, Takada T, Nakayama A, Nakashima H, Nakamura T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep. 2013;3:2014. https://doi.org/10.1038/srep02114.

  9. Schlesinger N, Thiele RG. The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis. 2010; 69:1907–1912.

    Article  CAS  PubMed  Google Scholar 

  10. Ea HK. Mechanisms of gout inflammation. PreseMed. 2011;40(9Pt1):836–43.

    Google Scholar 

  11. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2010;49(1):5–14.

    Article  PubMed  Google Scholar 

  12. Cronstein BN, Terkaltaub R. The inflammatory process of gout and its treatment. Arthritis Res. Ther. 2006;8:S1.

    Article  Google Scholar 

  13. Petrillie V, Martinn P. The inflammasome acute inflammatory diseases and gout. Joint Bone Spine. 2007;74:571–6.

    Article  Google Scholar 

  14. Martinon V, Petrilli A, Mayor A, Tardivel A, Tschopp J. Gout associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;44092081):237–241.

    Article  Google Scholar 

  15. Choi HK, Mpunt DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499–51616.

    Article  CAS  PubMed  Google Scholar 

  16. Graessler J, Graessle A., Unger S, Kopprsch S, Tausche AK, Kuhlisch E, et al. Association of human urate transporter-1 with reduced renal uric acid excretion and hyperuraecaemia in a German Caucasian population. Arthritis Rheum. 2006;54:292–300.

    Article  CAS  PubMed  Google Scholar 

  17. Dalbeth N, Merriman T. Crystal ball gazing: new therapeutic targets for hyperuraecaemia and got. Rheumatology. 2009;48:222–6.

    Article  CAS  PubMed  Google Scholar 

  18. Julkunen H, Konttinen YT. The clinical picture of gout is changing. Duodecim. 2010;126(12):1477–85.

    PubMed  Google Scholar 

  19. Ter Borg EJ, Rasker JJ. Gout in the elderly: a separate entity? Ann Rheum Dis. 1987;46:72–76.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Doherty M, Dieppe P. Crystal deposition in the elderly. Clin Rheum Dis. 1986;12:97–116.

    CAS  PubMed  Google Scholar 

  21. Centers for Disease Control and Prevention. Gout. http://www.cdc.gov/arthritis/basics/gout.htm retrieved 6 March 2015.

  22. Rott KJ, Agudedo CA. Gout. JAMA. 2003;289:2857–2860.

    Article  PubMed  Google Scholar 

  23. Yu T. Gout. In Katz WA ed. Diseases and Management of Rheumatic Diseases, ed. 2. Philadelphia. Lippincott Comp. 1988, pp 544–561.

    Google Scholar 

  24. Pittman JR, Bross MH. Diagnosis and management of gout. Am Fam Physician. 1999;59(7):1799–1806.

    CAS  PubMed  Google Scholar 

  25. McQueen FM, Reeves Q, Dalbeth N. New insights in an old disease: advanced imaging in the diagnosis and management of gout. Postgrad Med J. 2013;89;87–93.

    Article  PubMed  Google Scholar 

  26. Chowalloor PV, Siew TK, Keen HI. Imaging in gout. A review of recent developments. Ther Adv Musculoskelet Dis. 2014;8(4):136–143.

    Google Scholar 

  27. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology. 2007;46:1116–21.

    Article  CAS  PubMed  Google Scholar 

  28. Lai K, Chiu Y. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound. 2011;19:7–13.

    Article  Google Scholar 

  29. McQueen FM, Doyle A, Dalbeth N. Imaging in gout-what can we learn from MRI, CT, DECT and US? Arthritis Res Ther. 2011;13:246.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Schlesinger N. Management of acute and chronic gouty arthritis: present state of the art. Drugs. 2004;64(21):2399–416.

    Article  CAS  PubMed  Google Scholar 

  31. Cavagna L, Taylor WJ. The emerging role of biotechnological drugs in the treatment of gout. Biomed Res Int. 2014;2014:264859. https://doi.org/10.1155/2014/264859.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Wechalekar MD, Vinil O, Schlesnger N, Buchbinder R. Intra-articular of glucocorticoids for acute gout. Cochrane Database System, Rev 2011, https://doi.org/10.10002/1415185.cD009920.part2.

  33. McGill N. Management of acute gout. Aust Prescr. 2004;27:10–3.

    Article  Google Scholar 

  34. Khanna D, Khanna PB, Fitzgerald JD, Singh MK, Sangmee BAE, Neogi T et al. American College of Rheumatology. Guidelines and management of gout. Part 2 Therapy antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10): 1447–1461.

    Google Scholar 

  35. Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute gout in 181 hospitalized patients. Joint Bone Spine. 2013;80(3):291–4.

    Article  CAS  PubMed  Google Scholar 

  36. Morris I, Varughese G, Mattingly P. Lesson of the week-Colchicine in acute gout. BMJ. 2001;13:240–244.

    Google Scholar 

  37. Richette P. Gout: an overview of available urate lowering therapies. Ann Pharm Fr. 2012;70(3):33–8.

    Article  Google Scholar 

  38. George L, Sudy JS. Pegloticase for treating refractory chronic gout. Drugs Today (Brc). 2012;48(7):441–9.

    Google Scholar 

  39. Suresh E, Das P. Recent advances in management of gout. QJM. 2012;105(5):407–17.

    Article  CAS  PubMed  Google Scholar 

  40. Globalrph Gout treatment/Elevated uric acid levels. http://www.globalrph.com/gout.htm. accessed 7 March 2015.

  41. Avena-Woods C, Hilas O. Febuxostat (Uloric). A new treatment option for gout. Journal List. PT.v35(2);2010. PMC 2827920.

    Google Scholar 

  42. www.medscape.com/drug/krystexxa-pegloticase-99960.

  43. www.drugs.com/dosage/febuxostat.html.

  44. www.medicines.org.uk/emc/medicine/26935.

  45. Steika BS, May J. New gout managing guidelines: A quick and easy guide. Medscape. http://www.medscape.com/features/slideshow/gout#4 accessed 4 March 2015.

  46. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol. 2011;17(1):1–6.

    Article  PubMed  Google Scholar 

  47. Singh JA. The impact of gout on patient’s lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16:R132.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Khanna PP, Nuli G, Bardon T, Tauschi AK, Forsyth A, Goven A, et al. Tophi and frequent gout flares are associated: quality of life, productivity sand increased health care costs resource use: Results from a cross sectional survey. Health Quality Outcomes. 2012;10:117.

    Article  Google Scholar 

  49. Roddy Z, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case – control study. Rheumatology (Oxford). 2007;46:1441–1444.

    Article  CAS  PubMed  Google Scholar 

  50. Shields E, Besrd SM. A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics. 2015. https://doi.org/10.1007/s40273-015-0288-5.

  51. Smith E, Hoy D, Crooss M, Merriman TR, Vos T, Buchbinder R, Woolf A, et al. The global burden of gout: estimates from the Global Burden of Disease. 2010 study. Ann Rheum Dis. 2014;73(8):1470–6.

    Article  PubMed  Google Scholar 

  52. McCarty DJ. Crystal induced arthritis. Dis Mon 1994;40(6):255–59.

    Article  CAS  PubMed  Google Scholar 

  53. George RL Jr, Sundy JS. Pegloticase for treating refractory gout. Drugs Today (Barc). 2012;48(7):441–9.

    PubMed  Google Scholar 

  54. Winzer M, Grassler J, Aringer M. Crystal-induced arthritis-old but important. Z Rheumatol. 2007;66:317–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Sydney, Westmead Clinical School, Westmead, NSW, Australia

    Nages Nagaratnam & Kujan Nagaratnam

  2. Rehabilitation and Aged Care Service, Blacktown-Mt Druitt Hospital, Mount Druitt, NSW, Australia

    Gary Cheuk

Authors
  1. Nages Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kujan Nagaratnam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary Cheuk
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Nagaratnam, N., Nagaratnam, K., Cheuk, G. (2018). Crystal-Induced Arthritis. In: Geriatric Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-33434-9_57

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-33434-9_57

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-33433-2

  • Online ISBN: 978-3-319-33434-9

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation